SOMAI PRO Technology is a proprietary AI-based drug discovery technology of SOM Biotech. It is based on Artificial Intelligence and operates by the identification of Molecular field maps.
We successfully apply SOMAI PRO technology to identify drugs for the treatment of a specific disease and to discover new mechanisms of action and new applications for drugs. The main strength of our AI technology is that it identifies the mechanisms of action (biological activity) of molecules and determines its non-structural analogues with similar biological activity. It allows us to identify effective drugs as well as new applications for drugs with a high success rate and reliable patent protection. This is a key differentiating factor in relation to most of the other AI-based approaches, which use methods based on data mining, structural similarity, or the target structure.
SOMAI-PRO is suited to be applied for any therapeutic area and for new chemical entities. Specifically, the latter is a clear competitive advantage which enables us to accelerate and optimize drug discovery.
Clinically validated AI drug discovery technology
SOMAI-PRO is a clinically validated AI drug discovery technology. After defining drug candidates through the technology, we successfully finished the clinical phase 2a of two drugs with a very positive result. This will contribute to treating two relevant neurodegenerative diseases more effectively, meeting high safety and tolerance standards. One of our programs after phase 2a was out-licensed to NY based company. Moreover, we have 3 programs in the preclinical stage, and 20 more projects in our pipeline obtained through the technology.
We aim at developing value-creating partnerships with strategic partners, to leverage on the large intrinsic potential of SOMAI-PRO to discover new treatments to tackle some of the most acute diseases to accelerate the drug discovery process.